This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Dana-Farber-Cancer Institute Inc., The Broad Institute, Inc., The General Hospital Corporation. Active years: 2026.
Company Filing History:
1 out of 1,264 
1 out of 480 
1 out of 3,068 
Years Active: 2026
Title: Andrew Dunford: Innovator in Cancer Treatment
Introduction
Andrew Dunford is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment, particularly in the diagnosis and management of diffuse large B cell lymphomas (DLBCL). His innovative work has the potential to improve therapeutic outcomes for patients suffering from this aggressive form of cancer.
Latest Patents
Dunford holds a patent for a therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes. The patent outlines compositions and methods for the diagnosis and treatment or prevention of DLBCL. Specifically, it introduces a DLBCL classifier that identifies at least five distinct classes of DLBCL cancer, each with unique pathogenic mechanisms and outcomes. This classifier also recommends preferred therapeutic options, including combination therapies, tailored to each class of DLBCL cancer. He has 1 patent to his name.
Career Highlights
Throughout his career, Dunford has worked with prestigious institutions such as Dana-Farber Cancer Institute and The Broad Institute. His work in these organizations has allowed him to collaborate with leading experts in the field of oncology, further enhancing his research and contributions to cancer treatment.
Collaborations
Dunford has collaborated with notable colleagues, including Bjoern Chapuy and Margaret Shipp. These partnerships have played a crucial role in advancing his research and the development of innovative treatment strategies for DLBCL.
Conclusion
Andrew Dunford's contributions to cancer treatment through his innovative patent and collaborations with leading institutions and experts highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in the diagnosis and treatment of diffuse large B cell lymphomas.